FOLH1 and prostate carcinoma: This approach has been evaluated in prostate cancer, where an AI model integrating PSMA PET/CT results with standardized imaging criteria successfully tracking individual tumour changes, indicating its potential as a novel assessment tool for treatment response [45▪].